Beta Bionics, Inc. (BBNX) EBIT (2024 - 2026)

Beta Bionics (BBNX) has 3 years of EBIT data on file, last reported at -$24.3 million in Q1 2026.

• Quarterly EBIT fell 30.2% year-over-year to -$24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.3 million (down 42.01% YoY) and the FY2025 annual result came in at -$71.7 million, down 58.41% from the prior year.
• EBIT eased to -$24.3 million in Q1 2026 per BBNX's latest filing, from -$16.1 million in the prior quarter.
• The five-year high for EBIT was -$9.5 million in Q1 2024, with the low at -$24.3 million in Q1 2026.
• Average EBIT over 3 years is -$15.7 million, with a median of -$16.1 million recorded in 2025.
• The widest YoY moves for EBIT: up 23.68% in 2025, down 97.21% in 2025.
• Beta Bionics' EBIT stood at -$13.0 million in 2024, then decreased by 23.68% to -$16.1 million in 2025, then plunged by 50.53% to -$24.3 million in 2026.
• Business Quant data shows BBNX's EBIT at -$24.3 million in Q1 2026, -$16.1 million in Q4 2025, and -$17.0 million in Q3 2025.